Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,443 people get JAZZ articles and Market Currents by email alert.

Get email alerts on JAZZ »

JAZZ

Jazz Pharmaceuticals, Inc.

6/18/2013, 5:19 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 31, 12:53 PM Jazz Pharmaceuticals (JAZZ +0.9%) gets a bit of a lift from Stifel Nicolaus today, after the broker inititates the shares with a Buy and an $80 price target. The firm says that the stock's fundamentals are sound, but valuation still prices in concerns regarding the near to medium-term threat of generic entry on its lead narcolepsy product, Xyrem. Stifel however, thinks the company's extensive patent estate and proprietary distribution system should provide adequate protection at least through 2019. Comment! [Healthcare, On the Move]
Wednesday, May 8, 12:26 PM Jazz Pharmaceuticals (JAZZ -10%) gets slammed in spite of a solid Q1 earnings beat late yesterday, as investors focus on potential changes at the FDA which could lead the way to approving a generic version of JAZZ's narcolepsy medicine Xyrem, which is currently being produced by Roxane. Xyrem generated $117.5M in sales this quarter alone, nearly 60% of its revenue. Comment! [Healthcare, Earnings, On the Move]
Tuesday, May 7, 4:15 PM Jazz Pharma (JAZZ): Q1 EPS of $1.37 beats by $0.02. Revenue of $196.2M beats by $. Shares +5.1% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Tuesday, May 7, 12:10 AM Notable earnings after Tuesday’s close: ANDE, ARAY, AWK, AXLL, BIO, BIOL, BMC, BWC, CA, CDXS, CHRW, CODI, DGI, DGIT, DIS, DVA, EA, ENPH, EXEL, GA, GPOR, HTA, IAG, JAZZ, KGC, LYV, MAKO, MCEP, MCK, MDLZ, MITK, MRO, MYGN, NVTL, OAS, OCLR, OHI, ONXX, ORA, PRI, RBCN, SD, SGEN, SYMC, SYNC, TRIP, TWO, URS, VCLK, WBMD, WFM, WMB, WPZ, WTI, Z 1 Comment [Earnings]
Monday, May 6, 5:35 PM Notable earnings after Tuesday’s close: ANDE, ARAY, AWK, AXLL, BIO, BIOL, BMC, BWC, CA, CDXS, CHRW, CODI, DGI, DGIT, DIS, DVA, EA, ENPH, EXEL, GTEK, GA, GPOR, IAG, JAZZ, KGC, LYV, MAKO, MCEP, MCK, MDLZ, MITK, MRO, MYGN, NVTL, OAS, OCLR, OHI, ONXX, ORA, PRI, RBCN, SD, SGEN, SYMC, SYNC, TRIP, TWO, URS, VCLK, WBMD, WFM, WMB, WPZ, WTI, Z 1 Comment [Earnings]
Thursday, March 14, 1:36 PM Jazz Pharmaceuticals (JAZZ -0.4%) says regulators have given final approval to a generic version of the company's Luvox CR anti-depressant by Par Pharmaceutical. Additionally, Kohlberg Kravis Roberts (KKR) confirnms that it sold around 3.73M shares late last week at $58.28 each for $218.5M in gross proceeds, reducing its stake to around 6.5%. 1 Comment [Healthcare]
Monday, March 11, 11:59 AM Jazz Pharmaceuticals (JAZZ +0.9%) moves higher today after Cantor Fitzgerald starts coverage with a Buy rating and $86.00 price target. Cantor calls JAZZ an attractive growth story that's been held back by generic concerns over its key revenue driver, Xyrem, a drug for the treatment of narcolepsy, which represents 69% of revenue. Comment! [Healthcare, On the Move]
Monday, March 4, 7:00 PM Jazz Pharmaceuticals (JAZZ) announces plans for underwritten public offering of 5.375M shares of its stock held by certain shareholders. JAZZ will not receive any proceeds from the offering. Barclays is acting as sole book-running manager for the offering. Shares -2.1% AH. Comment! [Healthcare, On the Move]
Tuesday, February 26, 4:35 PM More on Jazz Pharma (JAZZ): Q4 EPS easily beats estimates. Net sales of Xyrem were $113.5M, compared to net sales of $71.8M for Q411. Gross margin was 85.8% compared to 95.2% for 2011. For FY13, the company expects an EPS of $5.70-5.90 on sales of $805M - 835M, above Street estimates of $5.67 on revenue of $811.3M. Shares +2% AH. Comment! [Healthcare, Earnings, On the Move]
Tuesday, February 26, 4:07 PM Jazz Pharmaceuticals (JAZZ): Q4 EPS of $1.53 beats by $0.12. Revenue of $183.7M misses by $0.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 26, 12:10 AM Notable earnings after Tuesday’s close: AVGO, AWK, DGI, DWA, EIX, FSLR, GA, GPOR, GWRE, HRZN, JAZZ, MAKO, MIDD, NUVA, ORA, PCLN, QCOR, RENN, REXX, RRC, SPN, STEC, TIVO, VNO, VRSK, ZAGG Comment! [Earnings]
Monday, February 25, 5:35 PM Notable earnings after Tuesday’s close: AVGO, AWK, DGI, DWA, EIX, FSLR, GA, GPOR, GWRE, HRZN, JAZZ, MAKO, MIDD, NUVA, ORA, PCLN, QCOR, RENN, REXX, RRC, SPN, STEC, TIVO, VNO, VRSK, ZAGG Comment! [Earnings]
Thursday, January 24, 4:48 AM The FDA won't appeal a decision to overturn the conviction of a salesmen who was found guilty of marketing narcolepsy drug Xyrem for treating drowsiness and chronic fatigue, two conditions for which the medicine wasn't approved. A court quashed the conviction because it said FDA regulations violated free speech in a decision that could have wide ramifications for the agency's ability to regulate off-label drug marketing. 3 Comments [Healthcare]
Thursday, December 13, 2012, 6:21 PM Jazz Pharmaceuticals (JAZZ) says the FDA has denied its 'Citizen Petition' filed in July, addressing requirements for the submission of any Abbreviated New Drug Application of any referencing Xyrem, including the ANDA submitted by Roxane Laboratories. JAZZ claimed the ANDA woulndn't have sufficient risk controls, but the agency said the ANDA would not have demonstrated the new generic drug product would have the same labeling and conditions of use as Xyrem. Comment! [Healthcare]
Monday, December 10, 2012, 7:35 PM Jazz Pharmaceuticals (JAZZ) presented data today from the largest safety trial to date of patients treated with Erwinaze for acute lymphoblastic leukemia who developed a hypersensitivity to E.coli-derived asparaginase. The trial, which was presented at the American Society of Hematology Annual Meeting and Exposition, includes additional follow up data that further describe the incidence of adverse events associated with Erwinaze treatment, which are consistent with the drug's known safety profile. Comment! [Healthcare]
Thursday, November 8, 2012, 4:22 PM Jazz Pharmaceutical (JAZZ): $1.29 misses by $0.03. Revenue of $175M misses by $4M. Shares -1% AH. (PR) 1 Comment [Healthcare, Earnings, On the Move]